AstraZeneca is out to get some more shots on goal in immunology, pairing up with a nascent biotech in hopes of developing oral medicines for psoriasis, arthritis and other diseases.
Australia-based Cynata said it is on track to manufacture mesenchymal stem cells at a commercial scale after validation of its Cymerus MSC manufacturing technology and has an eye on companies in Japan as it seeks partnerships to reach the market.
Taiwan's Twi Pharmaceuticals canceled its U.S. distribution and marketing agreement with Israel's Teva Pharmaceuticals for two generic drugs to have Twi's U.S. unit market them with its built-up sale network.
The Department of Defense has a habit of funding new medical technologies. This week it awarded a government contractor MRIGlobal $14.8 million for its proposed Sample-to-Sequence system to sequence the entire genome of pathogens and give a diagnosis within 24 hours.
Oncology company Heat Biologics is partnering with OncoSec, developer of the ImmunoPulse intratumoral DNA delivery platform. The two companies will evaluate the combination of the immunotherapy approaches developed by each company, according to the release.
Endo Pharmaceutical's investigational Belbuca buccal film strip for severe chronic pain has been accepted for review by the FDA, marking a win for the BioErodible MucoAdhesive technology to deliver drugs across mucosal surfaces like the inside of the cheek. And BEMA platform developer BioDelivery Sciences receives a $10 million milestone payment.
UPDATED: NIH funds studies of J&J's and GSK's injectable HIV meds, says daily pills lead to noncompliance
In bid to improve patient adherence, the U.S. National Institutes of Health is funding and helping run two clinical trials of long-acting injectable HIV candidates being developed by Johnson & Johnson's Janssen and GlaxoSmithKline.
South Korea's CTC Bio has out licensed rights to its drug-delivery technology to Swiss-based Ferring Pharmaceuticals, with the two companies to collaborate and develop in-vitro and in-vivo tests of drug prototypes.
Mylan Pharmaceuticals Private has signed an agreement with Gilead Sciences for exclusive rights in India to distribute the best-selling Sovaldi (sofosbuvir) and Harvoni combination with ledipasvir for treating hepatitis C.
Teijin and Nakashima Holdings are joining forces to try to claim a bigger share of the Japanese medical device market. Teijin is acquiring half of Nakashima Medical, a subsidiary of Nakashima Holdings, for about ¥1.5 billion ($12.6 million) as of April 1.